Immuneering (IMRX) Price & Analysis

Compare

429 Followers

IMRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.00 - $4.69

Previous CloseN/A

Volume3.55M

Average Volume (3M)805.34K

Market Cap

$128.47M

Enterprise Value$22.22M

Total Cash (Recent Filing)$35.87M

Total Debt (Recent Filing)$4.08M

Price to Earnings (P/E)―

Beta2.44

Next Earnings

Aug 06, 2025

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.42

Shares Outstanding35,985,703

10 Day Avg. Volume377,095

30 Day Avg. Volume805,338

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.17

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.35

Forecast

1Y Price Target

$7.50

Price Target Upside113.68% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe updated Phase 2a data continues to demonstrate an improved clinical profile, both on efficacy and safety, for the combo in first-line pancreatic cancer patients compared to GnP alone.

ManagementThe appointment of Dr. Igor Matushansky as the CMO brings extensive oncology drug development expertise to the company.

PartnershipsImmuneering announced a clinical supply agreement with Regeneron Pharmaceutical which will enable IMM-1-104 to be tested in combination with Libtayo in a Phase 2A study.

Bears Say

EarningsThe earnings report disclosed that management will be sharing initial data for IMM-1-104 in more than 30 patients in first-line pancreatic cancer.

Financial PerformanceIMRX reported an EPS of -$0.58 for the fourth quarter of 2024, lower than the consensus of -$0.43 with slightly higher R&D expenses.

Market CompetitionAnalysts look for updated Phase 2a data to be stronger to look competitive versus both standard of care and emerging treatments.

Immuneering News

Immuneering granted atebimetinib patent by USPTO

Immuneering (IMRX) announced that the U.S.Patent and Trademark Office, or USPTO, granted the company a composition of matter...

1M ago

IMRX

Immuneering price target raised to $10 from $8 at Mizuho

Mizuho raised the firm’s price target on Immuneering (IMRX) to $10 from $8 and keeps an Outperform rating...

2M ago

IMRX

Immuneering’s Promising Clinical Developments and Future Prospects Justify Buy Rating

Immuneering (IMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

2M ago

IMRX

Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly

Stock market futures are pointing lower as geopolitical risks in the Middle East have intensified. With tensions escalating...

2M ago

DYN

JBL

Immuneering Announces Promising Phase 2a Trial Results

Immuneering ( ($IMRX) ) has issued an announcement. On June 17, 2025, Immuneering Corporation announced interim data from...

2M ago

IMRX

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer

Immuneering (IMRX) announced positive data from its ongoing Phase 2a clinical trial evaluating atebimetinib, an oral, once-daily novel...

2M ago

IMRX

Immuneering Elects New Directors at Annual Meeting

Immuneering ( ($IMRX) ) has shared an announcement. On June 13, 2025, Immuneering Corporation held its Annual Meeting...

2M ago

IMRX

Positive Buy Rating for Immuneering Driven by Promising Clinical Data and Competitive Positioning

Immuneering (IMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

2M ago

IMRX

Immuneering price target lowered to $21 from $25 at Oppenheimer

Oppenheimer analyst Jay Olson lowered the firm’s price target on Immuneering (IMRX) to $21 from $25 and keeps...

3M ago

IMRX

Positive Outlook for Immuneering: Buy Rating Backed by Strategic Developments and Promising Clinical Data

Analyst Ami Fadia of Needham maintained a Buy rating on Immuneering (IMRX – Research Report), with a price...

3M ago

IMRX

Immuneering Corp. Reports Promising Q1 2025 Results

Immuneering Corp. Class A ( ($IMRX) ) has released its Q1 earnings. Here is a breakdown of the...

3M ago

IMRX

Immuneering reports Q1 EPS (42c), consensus (58c)

“In Q1, we showed that IMM-1-104 can drive exceptional efficacy for patients with pancreatic cancer, including a third-line...

3M ago

IMRX

Immuneering’s Promising Potential: Buy Rating Backed by Strategic Expansion and Data Generation

In a report released today, Ami Fadia from Needham maintained a Buy rating on Immuneering (IMRX – Research...

4M ago

IMRX

Immuneering Corp. Reports Promising Cancer Trial Results

Immuneering Corp. Class A ( ($IMRX) ) has released its Q4 earnings. Here is a breakdown of the...

5M ago

IMRX

IMRX FAQ

What was Immuneering’s price range in the past 12 months?

Immuneering lowest stock price was $1.00 and its highest was $4.69 in the past 12 months.

What is Immuneering’s market cap?

Immuneering’s market cap is $128.47M.

When is Immuneering’s upcoming earnings report date?

Immuneering’s upcoming earnings report date is Aug 06, 2025 which is 2 days ago.

How were Immuneering’s earnings last quarter?

Immuneering released its earnings results on May 05, 2025. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.527 by $0.107.

Is Immuneering overvalued?

According to Wall Street analysts Immuneering’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immuneering pay dividends?

Immuneering does not currently pay dividends.

What is Immuneering’s EPS estimate?

Immuneering’s EPS estimate is -0.4.

How many shares outstanding does Immuneering have?

Immuneering has 35,985,703 shares outstanding.

What happened to Immuneering’s price movement after its last earnings report?

Immuneering reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.527. Following the earnings report the stock price went down -1.401%.

Which hedge fund is a major shareholder of Immuneering?

Among the largest hedge funds holding Immuneering’s share is Perceptive Advisors LLC. It holds Immuneering’s shares valued at 0.

Immuneering Stock Smart Score

Outperform

Fundamentals

Return on Equity

-102.48%

Trailing 12-Months

Asset Growth

-42.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immuneering

Immuneering Corporation (IMRX) is a biopharmaceutical company focused on developing innovative drug candidates for the treatment of cancer and other diseases. The company's approach is centered around its proprietary platform that harnesses computational biology to unravel complex biological data and identify potential therapeutic targets. Immuneering aims to advance precision medicine by creating effective treatments that can precisely target specific disease pathways, offering new hope for patients with unmet medical needs.

Immuneering (IMRX) Earnings & Revenues

Historic Earnings Reports

IMRX Stock 12 Month Forecast

Average Price Target

$7.50

▲(113.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,3.9446153846153846,4.44923076923077,4.953846153846154,5.458461538461538,5.963076923076923,6.4676923076923085,6.972307692307693,7.476923076923077,7.981538461538461,8.486153846153847,8.990769230769232,9.495384615384616,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,3.752307692307692,4.064615384615385,4.376923076923077,4.689230769230769,5.001538461538462,5.313846153846153,5.626153846153846,5.938461538461539,6.250769230769231,6.563076923076924,6.875384615384616,7.187692307692307,{"y":7.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.44,3.4446153846153846,3.4492307692307693,3.453846153846154,3.4584615384615383,3.463076923076923,3.4676923076923076,3.4723076923076923,3.476923076923077,3.4815384615384617,3.486153846153846,3.4907692307692306,3.4953846153846153,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.53,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >